Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double-blind, placebo-controlled study

Radiotherapy and Oncology

Volumn 100, Issue 1, 2011, Pages 62-69

  Gregoire, Vincent ^a   Hamoir, Marc ^a   Chen, Changhu ^b   Kane, Madeleine ^b   Kawecki, Andrzej ^c   Julka, Pramod K ^d   Wang, Hung Ming ^e   Prasad, Srihari ^f   D'Cruz, Anil K ^g   Radosevic Jelic, Ljiljana ^h   Kumar, Rejnish R ⁱ   Korzeniowski, Stanislaw ^j   Fijuth, Jacek ^k   MacHiels, Jean Pascal ^a   Sellers, Mark V ^l   Tchakov, Ilian ^l   Raben, David ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^g TATA MEMORIAL HOSPITAL   (India)

^h INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

ⁱ REGIONAL CANCER CENTRE   (India)

^j INSTITUTE OF ONCOLOGY   (Poland)

^k M Kopernika ^*  (Poland)

^l ASTRAZENECA   (United Kingdom)

more..

Author keywords

Cisplatin; Gefitinib; Radiotherapy; Randomized phase II; SCCHN

Indexed keywords

CISPLATIN; GEFITINIB; PLACEBO;

ACNE; ADULT; ANEMIA; ARTICLE; ASTHENIA; BODY WEIGHT; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN INJURY; SORE THROAT; SQUAMOUS CELL CARCINOMA; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DOUBLE-BLIND METHOD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES;

EID: 80051781911     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.07.008     Document Type: Article

References (35)

1. W. Budach, T. Hehr, V. Budach, C. Belka, and K. Dietz A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck BMC Cancer 6 2006 28
2. J.P. Pignon, J. Bourhis, C. Domenge, L. Designé on behalf of the MACH-NC Collaborative Group Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data Lancet 355 2000 949 955 (Pubitemid 30148259)
3. J.P. Pignon, A. Le Maître, E. Maillard, and J. Bourhis Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol 92 2009 4 14
4. D.J. Adelstein, Y. Li, and G.L. Adams An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21 2003 92 98
5. D.M. Brizel, M.E. Albers, and S.R. Fisher Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer N Engl J Med 338 1998 1798 1804 (Pubitemid 28277960)
6. D. Rischin, L.J. Peters, and B. O'Sullivan Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group J Clin Oncol 28 2010 2989 2995
7. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578 (Pubitemid 43209104)
8. L. Milas, K. Mason, and N. Hunter In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 2000 701 708 (Pubitemid 30111496)
9. N. Zhang, K. Erjala, and J. Kulmala Concurrent cetuximab, cisplatin and radiation for squamous cell carcinoma of the head and neck in vitro Radiother Oncol 92 2009 388 392
10. C. Chen, M. Kane, and J. Song Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer J Clin Oncol 25 2007 4880 4886 (Pubitemid 350220417)
11. J.D. Hainsworth, D.R. Spigel, and H.A. Burris III Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck Cancer 115 2009 2138 2146
12. D.G. Pfister, Y.B. Su, and D.H. Kraus Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm J Clin Oncol 24 2006 1072 1078 (Pubitemid 46638804)
13. T.Y. Seiwert, D.J. Haraf, and E.E. Cohen Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer J Clin Oncol 26 2008 1732 1741
14. K.K. Ang, B.A. Berkey, and X. Tu Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356 (Pubitemid 36025259)
15. M. Baumann, M. Krause, and E. Dikomey EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms Radiother Oncol 83 2007 238 248 (Pubitemid 46915540)
16. L. Milas, K.A. Mason, and K.K. Ang Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings Int J Radiat Biol 79 2003 539 545 (Pubitemid 37314010)
17. J.G. Eriksen, T. Steiniche, J. Askaa, J. Alsner, and J. Overgaard The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck Int J Radiat Oncol Biol Phys 58 2004 561 566 (Pubitemid 38142484)
18. J.G. Eriksen, F.M. Buffa, J. Alsner, T. Steiniche, S.M. Bentzen, and J. Overgaard Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas Radiother Oncol 72 2004 275 282 (Pubitemid 39265380)
19. K.K. Ang, N.H. Andratschke, and L. Milas Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy Int J Radiat Oncol Biol Phys 58 2004 959 965 (Pubitemid 38221156)
20. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
21. E.E. Cohen, M.A. Kane, and M.A. List Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Clin Cancer Res 11 2005 8418 8424 (Pubitemid 41746956)
22. E.E.W. Cohen, F. Rosen, and W.M. Stadler Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 2003 1980 1987 (Pubitemid 46606387)
23. J.S.W. Stewart, E.E.W. Cohen, and L. Licitra Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck J Clin Oncol 27 2009 1864 1871
24. V. Gregoire, E. Coche, G. Cosnard, M. Hamoir, and H. Reychler Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience Radiother Oncol 56 2000 135 150 (Pubitemid 30601670)
25. V. Gregoire, P. Levendag, and K.K. Ang CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines Radiother Oncol 69 2003 227 236 (Pubitemid 37485996)
26. Prescribing, recording and reporting photon beam therapy. Report 50. Journal of the International Commission on Radiation Units and Measurements. Oxford: Oxford University Press; 1993.
27. Prescribing, recording and reporting photon beam therapy (supplement to ICRU Report 50). Report 62. Journal of the International Commission on Radiation Units and Measurements. Oxford: Oxford University Press; 1999.
28. J. Shafiq, M. Barton, and D. Noble An international review of patient safety measures in radiotherapy practice Radiother Oncol 92 2009 15 21
29. D.I. Thwaites, and D. Verellen Vorsprung Durch Technik: evolution, implementation, QA and safety of new technology in radiotherapy Radiother Oncol 94 2010 125 128
30. L.J. Peters, B. O'Sullivan, and J. Giralt Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02 J Clin Oncol 28 2010 2996 3001
31. S.M. Bentzen, and A. Trotti Evaluation of early and late toxicities in chemoradiation trials J Clin Oncol 25 2007 4096 4103 (Pubitemid 47492954)
32. L. Walsh, C. Gillham, and M. Dunne Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC) Radiother Oncol 98 2011 38 41
33. G. de Castro Jr., I.M. Snitcovsky, and E.M. Gebrim High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma Eur Arch Otorhinolaryngol 264 2007 1475 1482 (Pubitemid 350112409)
34. P. Lassen The role of human papillomavirus in head and neck cancer and the impact of radiotherapy outcome Radiother Oncol 95 2010 371 380
35. K.K. Ang, J. Harris, and R. Wheeler Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 2010 24 35